AllSight
Companies · PCVX · Biological Products, (No Diagnostic Substances)

Vaxcyte, Inc. (PCVX)

Vaxcyte, Inc. (PCVX) stock — the fundamentals (P/E, market cap, valuation) and every material event, decoded in plain English.

Vaxcyte, Inc. (PCVX) stock — financials & valuation

Key numbers for Vaxcyte, Inc. (PCVX): P/E ratio, market cap, profit margins, returns, and whether the stock looks cheap or expensive versus its own 5-year range.

AllSight quality score: 36/100 — a percentile rank of Vaxcyte, Inc.’s fundamentals against Manufacturing peers, weakest on growth. A quality ranking, not a price prediction.

Market cap$8.5B
EV / EBITDA-7.3×
Return on equity-38.6%
ROIC-45.3%
Debt / equity0.0×
Dividend yield0.0%

Is Vaxcyte, Inc. overvalued? P/B looks fair vs its 5-year range.

Independent of the events above — derived from Vaxcyte, Inc.’s own financial statements and shown as context, never as advice.

Sep 3, 2026Guidance reaffirmed
Vaxcyte tightens VAX-31 readout timing, adds veteran vaccine leadership
Related companies in Biological Products, (No Diagnostic Substances)
Open live on AllSight — the whole market, decoded →

About AllSight · Editorial standards & method · Contact